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Mutations of POLR3A Encoding a Catalytic Subunit
of RNA Polymerase Pol III Cause a Recessive
Hypomyelinating Leukodystrophy
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Giovanni Carosso,4 Isabelle Cle´ment,3 Odile Boespflug-Tanguy,5,6,7,8 Diana Rodriguez,8,9,10
Vale´rie Delague,11 Joelle Abou Ghoch,2 Nadine Jalkh,2 Imen Dorboz,7,8 Sebastien Fribourg,12
Martin Teichmann,12 Andre´ Megarbane,2,13 Raphael Schiffmann,14 Adeline Vanderver,4
and Bernard Brais3,*
Leukodystrophies are a heterogeneous group of inherited neurodegenerative disorders characterized by abnormal whitematter visible by
brain imaging. It is estimated that at least 30% to 40% of individuals remain without a precise diagnosis despite extensive investigations.
Wemapped tremor-ataxia with central hypomyelination (TACH) to 10q22.3-23.1 in French-Canadian families and sequenced candidate
genes within this interval. Two missense and one insertion mutations in five individuals with TACH were uncovered in POLR3A, which
codes for the largest subunit of RNA polymerase III (Pol III). Because these families were mapped to the same locus as leukodystrophy
with oligodontia (LO) and presented clinical and radiological overlap with individuals with hypomyelination, hypodontia and
hypogonadotropic hypogonadism (4H) syndrome, we sequenced this gene in nine individuals with 4H and eight with LO. In total,
14 recessive mutations were found in 19 individuals with TACH, 4H, or LO, establishing that these leukodystrophies are allelic.
No individual was found to carry two nonsense mutations. Immunoblots on 4H fibroblasts and on the autopsied brain of an individual
diagnosed with 4H documented a significant decrease in POLR3A levels, and there was a more significant decrease in the cerebral
white matter compared to that in the cortex. Pol III has a wide set of target RNA transcripts, including all nuclear-coded tRNA. We
hypothesize that the decrease in POLR3A leads to dysregulation of the expression of certain Pol III targets and thereby perturbs cyto-
plasmic protein synthesis. This type of broad alteration in protein synthesis is predicted to occur in other leukoencephalopathies
such as hypomyelinating leukodystrophy-3, caused by mutations in aminoacyl-tRNA synthetase complex-interacting multifunctional
protein 1 (AIMP1).Leukodystrophies are a heterogeneous group of inherited
neurodegenerative disorders characterized by abnormal
central-nervous-system white matter.1 It is estimated that
at least 30% to 40% of individuals still remain without
a precise diagnosis despite extensive investigations.2 We
recently described tremor-ataxia with central hypomyeli-
nation (TACH), a form of childhood-onset hypomyelinat-
ing leukodystrophy with prominent tremor and cerebellar
signs and mapped its locus to 10q22.3-q23.31.3 Another
hypomyelinating leukodystrophy, leukodystrophy with
oligodontia (LO) (MIM 607694), was also mapped to
10q22 in a Syrian family.4,5 Both TACH and LO have clin-
ical and radiological overlap with another unmapped form
of hypomyelinating leukodystrophy referred to as hypo-
myelination with hypodontia and hypogonadotropic
hypogonadism (4H) syndrome (MIM 612440).6–9 In this
study, we report that the three conditions are allelic and
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(rs2116829-rs927452), containing approximately 15
genes. Considering the relatively small size of the interval
and the fact that it includes ten promising candidate
genes, we chose to sequence these genes rather than
perform next-generation sequencing. Sequencing of the
exons, exon-intron boundaries, and 30 and 50 untranslated
regions (UTRs) of the following six genes did not uncover
any mutation: eukaryotic translation initiation factor
5A-like 1 (EIF5AL1), potassium large conductance cal-
cium-activated channel, subfamily M, alpha member 1
(KCNMA1 [MIM 600150]), peptidylprolyl isomerase F
precursor (PPIF [MIM 604486]), ribosomal protein S24
isoform b (RPS24 [MIM 602412]), pulmonary surfactant-
associated protein A1 (SFTPA1 [MIM 178630]), pulmonary
surfactant-associated protein A2 (SFTPA2 [MIM 178642]).
POLR3A was considered a candidate gene because it is
responsible for tRNA and 5S transcription that, if per-
turbed, should have an impact on protein synthesis.
Sequencing of the 31 exons, exon-intron boundaries,
and 50 and 30 UTRs of POLR3A (NM_007055.3) uncovered
a homozygous missense c.2015G>A (p.Gly672Glu) muta-
tion in POLR3A in 3 out of 4 TACH families from the
same region of Quebec: families II (individuals 2–4), III
(individual 5), and IV (individual 6) (Table 1). Individuals
2 and 3 are brothers and their parents are consanguineous,
whereas individual 4 is a deceased distant cousin. The
parents of individual 5 are distantly related, whereas the
parents of individual 6 are not known but are suspected
to be related. The other individual with TACH (individual
1, family I) carries two different mutations: c.1674C>G
(p.Phe558Leu) and c.3742insACC (p.1248insThr) (Table 1).
Sequencing of POLR3A in individuals with LO uncovered
the following mutations: c.2003þ18G>A (p.Tyr637-
CysfsX650) in the previously published consanguineous
Syrian family5 (family X, where individuals 12–15 are sib-
lings and individuals 16–17 are their first-degree cousins),
c.418C>T (p.Arg140X) and c.2554A>G (p.Met852Val) in
the European individual, and c.2171G>A (p.Cys724Tyr)
in the Guatemalan individual (Table 1). The clinical over-
lap between TACH, LO, and 4H led to the sequencing of
nine individuals with 4H. Five individuals with 4H were
compound heterozygotes for mutations in POLR3A,
whereas in four clinically similar individuals with 4H, no
mutations were uncovered. Individuals 7, 8, 9, and 10
were part of the original individuals with 4H described.8
In total, 19 individuals belonging to 12 families were
found to be homozygotes or compound heterozygotes
for 14 different putative POLR3A mutations: eight
missense, one three-base-pairs insertion, three nonsense,
and two splice-site mutations (Table 1). Among them,
nine mutations result in amino acid change or insertion
in regions that are highly conserved across different
species (Figure 1). None of the participants are homozy-
gous for nonsense mutations. All parents were unaffected
and found to carry one of their affected child’s mutations,
whereas unaffected siblings were never found to carry two
mutations. All variants were absent in more than 250416 The American Journal of Human Genetics 89, 415–423, SeptembFrench-Canadian, European, and Lebanese control chro-
mosomes.
The locations of the different missense mutations are
represented in Figure 1. Pol III’s POLR3A (RPC1) and Pol
lI’s POLR2A (RPB1) subunits are highly-conserved proteins
that display an overall similar structure even though some
minor local differences because of subunit-specific
sequences are anticipated.11 Extrapolating the yeast Pol II
structure (PDB 1WCM) onto POLR3A (RPC1), we expect
the p.Gln1336X mutation in human POLR3A to be
located on the clamp region of Pol III, which corresponds
to Glu1417 in POLR2A (RPB1). This mutation is located
in an area where the specific subunits POLR3C/POLR3F
(RPC62/RPC39) and POLR3G (RPC32) have been localized
by immunolabeling and electron microscopy.12,13 The
effect of this mutation is probably drastic and most likely
corresponds to an important alteration of the interaction
of the ternary POLR3G/POLR3C/POLR3F (RPC32/RPC62/
RPC39) complex and/or of the POLR3H/CRCP (RPC8/9)
complex (analogous to POLR2D/POLR2G or RPB4/7)
with the remainder of the polymerase. The p.Met852Val
and p.Cys724Ile mutations in POLR3A correspond to the
residues Met818 and Val690 in POLR2A (RPB1). The
p.Met852Val mutation is located in the cleft region of
the polymerase on the bridge helix where incoming
double-stranded DNA lies during transcription. The
p.Cys724Ile mutation is located in the external 2 region.
The p.Asp372Asn (Asp356) and p.Gly672Glu (Gly638)
mutations are located in the lobe and the so-called external
1 regions, respectively, that are positioned close by the
AC19 subunit of Pol III, which is related to the POLR2J
(RPB11) subunit of Pol II. The p.Asn775Ile mutation in
POLR3A corresponds to Asn741 in POLR2A, which is
located in the external 1 region of Pol II. The p.Phe558Leu,
p.Ser636Tyr, and p.Arg1005Cys mutations in POLR3A
correspond to Phe540, Asn603, and Arg1036 residues in
POLR2A and are located at the end of the fork region,
the external 2, and the hybrid binding areas of POLR2A
(RPB1), respectively. They are all located in the vicinity of
POLR2H (RPB8) (a shared subunit between Pol I, Pol II,
and Pol III). These mutations might alter the local environ-
ment, leading to modified interaction of the polymerase
with its RPB8 subunit.
The three nonsense mutations and the two splice-site
mutations were predicted to lead to truncated proteins of
different sizes (Figure 1). The six individuals from the large
Syrian LO family X are homozygote for an intronic variant
c.2003þ18G>A (p.Tyr637CysfsX650), whereas two indi-
viduals with 4H from families V and VIII share the same
c.2711-1G>A (p.Arg873AlafsX878) intronic variant. The
mutational impact of these two variants was assessed
with Splice View and Slice Port. The Syrian G to A substitu-
tion at position c.2003þ18 was predicted to create a new
donor splice site, and this was confirmed by RT-PCR and
sequencing of the PCR products. This mutation causes
the retention of 19 nucleotides from intron 14 leading to
an addition of six amino acids to the protein, changinger 9, 2011
the reading frame and a premature stop codon at position
650. RT-PCR amplification revealed that both the normal
and the aberrantly spliced products are produced, suggest-
ing that some normal POLR3A is still expressed (Figure S1,
available online). The mutation c.2711-1G>A is predicted
to remove an acceptor site; lead to the use of a cryptic
acceptor site located in exon 20, five base pairs past the
original site; and cause a change in the reading frame
and a premature stop codon at position 878.
The role of Pol III as a housekeeping gene might explain
the absence of individuals with two null alleles. The nature
of the uncovered mutations suggests a rather hypomor-
phic dysfunction of Pol III because of a decreased abun-
dance of POLR3A or abnormal interactions of POLR3A
with DNA, other Pol III subunits, or transcription factors.
We performed immunoblots by using the previously vali-
dated hRPC155 antibody14 in whole-cell lysates derived
from the fibroblasts of four individuals with 4H to assess
whether POLR3A levels are indeed reduced (Figures 2A
and 2B). The relative ratio of POLR3A, which is normalized
to actin in fibroblasts, from affected individuals is signifi-
cantly lower (23.4%) than in controls (Figure 2B). The
relative ratio of the four individuals with 4H versus the
two controls is also reduced, and this was shown to be
statistically significant (p ¼ 0.001) (Figure 2C). These
results suggest that regardless of the nature of the muta-
tions, POLR3A is less abundant in fibroblasts from affected
individuals. To establish whether POLR3A was also re-
duced in the central nervous system, we performed an
immunoblot on protein extracts from the brain of indi-
vidual 9, who was diagnosed with 4H and was a carrier of
one missense mutation and one nonsense mutation, and
we compared this immunoblot to that of an age-matched
control (Figure 2D). Figure 2E shows a significant reduction
in POLR3A levels in the cortex and cerebral white matter.
The most significant decrease was observed in the white
matter of those with 4H (26.8%, p ¼ 0.006) compared to
the white matter of the control (Figure 2E).
POLR3A mutations cause three overlapping leukodys-
trophy phenotypes (Table 1). These individuals all have
in common progressive upper motor neuron dysfunction
as well as some degree of cerebellar involvement and
cognitive regression. Mean age of loss of ambulation in
this cohort is 16.1 years. They also all demonstrate a hypo-
myelinating pattern on MRI; there is isointense or only
minimally hypointense white matter in T1-weighted
images and hyperintense white matter in T2-weighted
images.15 The deep white matter is preferentially involved,
and of the U-fibers are relatively spared (Figure 3). Less
constant MRI findings include a thin corpus callosum
and preferential vermian cerebellar atrophy. Despite their
clinical and radiological similarities, TACH, LO, and 4H
have some distinct features suggesting that Pol III-related
leukodystrophies correspond to a spectrum with inter-
and intrafamilial variability. Individuals with TACH have
the earliest age of onset and are more likely to present in
childhood with developmental delays. In our cohort, indi-The Americanviduals with TACH required a wheelchair for daily use
earlier than individuals with 4H or LO, at a mean age of
8.25 years, though two individuals are still ambulatory at
ages 14 and 19. The severity of the disease is highly variable
in individuals with TACH homozygote for the same
c.2015G>A mutation, even in the same family. Eye-move-
ment abnormalities such as an abnormal smooth pursuit
and vertical gaze limitations were seen more commonly
in TACH and 4H syndrome than in LO. Although optic
atrophy was a frequent feature in TACH (four out of six
individuals), it was not seen in LO and 4H. Peripheral-
nerve involvement is also not a constant finding. Nerve
biopsies were performed in three of the five individuals
with 4H and showed the typical abnormalities described
in this disorder visible by electron microscopy: clefts lined
with granular debris, expanded abaxonal space, outpocket-
ing with vacuolar disruption, and loss of normal myelin
periodicity.8 Nerve biopsies performed on two individuals
with TACH and one individual with LO were completely
normal. Although hypodontia was present in all individ-
uals with 4H or LO in this cohort, it was only observed
in two out of six individuals with TACH. Hypogonado-
tropic hypogonadism was by definition seen in all individ-
uals with 4H but was found in only two out of six individ-
uals with TACH and none of the individuals with LO.
However, the young age of some of the individuals with
LO and TACH might have prevented a diagnosis of hypo-
gonadotropic hypogonadism. Therefore, hypodontia and
hypogonadotropic hypogonadism are not universally
found in Pol III-related leukodystrophies but when present
should encourage clinicians to search for POLR3A muta-
tions. Only the identification of a greater number of
POLR3A-mutation-proven cases of hypomyelinating
leukodystrophy will allow a better definition of the full
clinical spectrum and a genotype-phenotype correlation.
Only recently, the first human mutations in POLR1D,
a shared subunit of Pol I and Pol III, were found to cause
a dominant developmental disease with no central
nervous disease involvement: Treacher Collins syndrome
(TCS [MIM 154500]).16 The uncovering of recessive muta-
tions in other individuals with TCS in the gene encoding
the Pol I subunit POLR1C closely interacting with POLR1D
suggests that Pol I rather than Pol III dysregulation is more
central to TCS’s pathophysiology. Nuclei of human cells
contain three DNA dependent RNA polymerases (Pol I,
Pol II, and Pol III) that are each responsible for the tran-
scription of specific sets of genes.17 Pol I transcribes the
large ribosomal RNA that is subsequently processed into
28S, 18S, and 5.8S RNAs, which represent major constitu-
ents of the ribosome.18 Pol II transcribes all protein coding
messenger RNA (mRNA), most small nuclear RNAs
(snRNAs), small nucleolar RNAs, and probably all micro-
RNAs (miRNAs).18 Pol III is involved in the transcription
of small RNAs that do not code for proteins but that are
essential for the regulated execution of gene expression
programs. These Pol III transcribed RNAs include transfer
RNAs (tRNAs), the ribosomal 5S RNA, U6 snRNA, andJournal of Human Genetics 89, 415–423, September 9, 2011 417
Table 1. Mutations and Clinical Features of Pol III-Related Leukodystrophies
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1 I FC TACH c.1674C>G p.Phe558Leu M 2 þ þ 

 þ þ    þ þ þ þ 5   N/A 
c.3742insACC p.1248insThr
2 II FC TACH c.2015G>A p.Gly672Glu M 1 þ þ þ þ þ þ þ þ þ þ þ þ þ 8 þ  N/A 
3 II FC TACH c.2015G>A p.Gly672Glu M 5 þ þ    þ    þ þ þ   þ  N/A 
4 II FC TACH c.2015G>Aa p.Gly672Glua F 3  þ  þ  þ  þ þ þ þ þ þ 8    21
5 III FC TACH c.2015G>A p.Gly672Glu M 3  þ  þ þ þ þ þ þ þ þ þ þ 12  þ  
6 IV FC TACH c.2015G>A p.Gly672Glu F 5  þ  þ  þ   þ þ þ þ    þ N/A 
7 V W USA 4H c.2554A>G p.Met852Val F 13  þ 5   þ þ þ þ þ  þ þ 24 þ þ þ 
c.2711-1G>A p.Arg873AlafsX878
8 VI AA USA 4H c.2324A>T p.Asn775Ile F 0 þ þ    þ þ þ þ þ  þ þ 10 þ þ N/A 
c.1114G>A p.Asp372Asn
9 VII W USA 4H c.2830G>T p.Glu944X M 13  þ 5   þ þ þ  þ  þ þ 30 þ þ þ 36
c.3013C>T p.Arg1005Cys
10 VIII W USA 4H c.2554A>G p.Met852Val F 12  þ    þ þ þ  þ  þ þ 24 þ þ þ 
c.2711-1G>A p.Arg873AlafsX878
11 IX France 4H c.4006C>T p.Gln1336X F 1 þ þ    þ    þ þ þ   þ þ N/A 
c.1907C>A p.Ser636Tyr
12 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 M 13  þ        þ  þ þ 23 þ  N/A 28
13 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 F 12  þ        þ þ þ þ 20 þ  N/A 
14 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 F 11  þ        þ þ þ þ 20 þ  N/A 
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15 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 F 11  þ        þ  þ   þ  N/A 
16 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 M 12  þ        þ  þ   þ  N/A 
17 X Syria LO c.2003þ18G>A p.Tyr637CysfsX650 M 12  þ        þ  þ   þ  N/A 
18 XI W Europe LO c.418C>T p.Arg140X F 3 þ þ    þ    þ þ þ   þ   
c.2554A>G p.Met852Val
19 XII Guatemala LO c.2171G>A p.Cys724Tyr M 2 þ þ    þ þ  þ þ þ þ þ 9 þ N/A N/A 
POLR3A mutations and clinical features of individuals with TACH, 4H, and LO. A total of 14 different mutations were found: missense, nonsense, insertion, and splice-site mutations. Individuals 1-53 and 610 with TACH,
individuals 7-108 with 4H and individuals 12-174,5 with LO have been published previously. The following abbreviations are used:þ, positive or present;, negative or absent; FC, French-Canadian; AA USA, African American
from USA; W Europe, white from Europe; W USA, white from USA; F, female; M, male; and N/A, not available.
a Presumed mutation the deceased individual 4 for which DNA was not available.
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Figure 1. POLR3A Mutations
(A) Schematic representation of POLR3A exonic mutations. Missense and nonsense mutations are depicted according to the different
POLR3A (RPC1) domains (modified from Ensembl). The amino acid conservation across species is shown for all missense and nonsense
mutations. The following abbreviations are used in the upper panel: RNA_pol_Rpc1_1, RNA_pol_Rpc1_3, RNA_pol_Rpc1_4, and
RNA_pol_Rpc1_5, RNA polymerase subunit domains one, three, four and five; and RNA_pol_asu, RNA polymerase alpha subunit.
The following abbreviations are used in the lower panel: C. elegans, Caenorhabditis elegans; D. melanogaster, Drosophila melanogaster;
D. rerio, Danio rerio; H. sapiens, Homo sapiens; M. musculus, Mus musculus; and S. cerevisiae, Saccharomyces cerevisiae.
(B)Three-dimensional representations of POLR3A missense and nonsense mutations. Point mutations identified in POLR3A are dis-
played according to their equivalent positions in the yeast RNA Polymerase II RPB1 subunit.27 Numbers in brackets refer to the positions
in yeast RPB1. Images have been generated with PyMol software (Schro¨dinger). For imaging purposes, the RPB5 subunit has been
omitted from the figure. RPB1 is shown in blue, RPB2 in green, RPB7 in brown, RPB4 in pink, RPB8 in orange, and RPB11 in magenta.7SK RNA, as well as small interspersed repetitive sequences
(SINEs).17,19,20 Pol III’s transcription is cell-type and cell-
cycle dependent20 and is dysregulated during cellular
transformation.17,21 RNA polymerases are multisubunit
complexes that are composed of 12 (Pol II), 14 (Pol I), or
17 (Pol III) subunits. They are highly-conserved and impor-
tant homologies have been found between the three Pols.
POLR3A encodes the largest subunit of Pol III, which,
together with POLR3B, constitutes the RNA catalytic site
of Pol III.22 POLR3A interacts with multiple subunits of
Pol III, including subunits that are common to all three
RNA polymerases (POLR2E, POLR2F, POLR2H, and420 The American Journal of Human Genetics 89, 415–423, SeptembPOLR2K) and two that are shared by Pol I and Pol III
only (POLR1C and POLR1D).12 In addition, POLR3A inter-
acts with subunits specific to Pol III, most notably POLR3G
that forms a ternary subcomplex with POLR3C and
POLR3F, which is positioned between POLR3A and its tran-
scription initiation factors.17,22
Considering that Pol III is central to tRNA production,
it is tempting to hypothesize that POLR3A mutations
lead to dysregulation of Pol III, which could influence
relative levels of certain tRNA that are known to be more
abundant in the central nervous system.23 Two other leu-
koencephalopathies are caused by mutations in geneser 9, 2011
Figure 2. Immunoblots of Fibroblasts and Brain Lysates from Individuals with 4H and from Controls
(A) POLR3A immunoblot of 4H fibroblasts versus controls. Cultured fibroblasts were lysed with RIPA buffer. Protein samples were electro-
phoresed with SDS-PAGE and blotted onto nitrocellulose membranes. Immunoblots were imaged with QuantityOne software (BioRad)
and the density of each was quantified across triplicate experiments and averaged with normalization to a loading control (actin).
A typical image of POLR3A immunoblot done on 4H and control fibroblasts with anti-hRPC155 at 1:2000 dilution.14 From left to right,
samples are control 1 and 2 and individuals 7, 8, 9, and 10.
(B) Ratio of POLR3A in 4H fibroblasts versus in control fibroblasts. Actin was used as a loading control. Controls are shown in white, and
individuals with 4H are shown in gray. Standard error calculation is reported for repeated experiments.
(C) Ratio of POLR3A in 4H fibroblasts versus two control fibroblasts showing 21.67% decrease of POLR3A in 4H fibroblasts (p ¼ 0.001).
The average of two controls is shown in white, and the average of the individuals with 4H is shown in gray. Standard error calculation is
reported for repeated experiments. Statistical analysis was carried out with a student t test.
(D) Immunoblot of the brain of individual 9 compared to the brain of a control. Typical image of a POLR3A immunoblot done on the
cortex and white matter of individual 9, diagnosed with 4H, and an age-matched control with anti-hRPC155 at 1:2000 dilution. The
control is shown in white, and the individual with 4H is shown in gray. From left to right, samples are a control cortex, a 4H cortex,
control white matter, and 4H white matter.
(E) Relative ratio of POLR3A in the brain of individual 9, affected by 4H syndrome versus that in a control; there is a 6.8% decrease of
POLR3A in the 4H cortex compared to a control (p ¼ 0.009) and a 26.8% decrease of POLR3A in 4H white matter compared to that in
a control (p ¼ 0.006). Standard error calculation is reported for repeated experiments. Statistical analysis was carried out with a student
t test.important for protein synthesis: leukoencephalopathy
with spinal cord involvement and lactate elevation
(LBSL [MIM 611105]) caused by mutations in the
nuclear-coded mitochondrial aspartyl-tRNA synthetase
(DARS2 [MIM 610956]) and hypomyelinating leukodys-
trophy-3 (MIM 260600) caused by mutation in amino-
acyl-tRNA synthetase complex-interacting multifunc-
tional protein 1 (AIMP1/p43 [MIM 603605]) important
for proper cytoplasmic protein synthesis.24–26 Pol III-
related leukodystrophies and these other leukoencephalo-
pathies could reflect the vulnerability of the central
nervous system to adequate expression of certain tRNAs
during development.
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Figure 3. MRI Findings in 4H Subject 9
(A) Axial T2-weighted image of the brain at
the level of the pons.
(B) Axial T2-weighted image of the brain at
the level of the basal ganglia.
(C) Sagittal T1-weighted image of the brain
at the midline.
(D) Axial T1-weighted image of the brain
at the level of the pons.
(E) Axial T1-weighted image of the brain at
the level of the basal ganglia.
As previously described,15 this case dem-
onstrates the features characteristic of 4H
visible through neuroimaging: cerebellar
white matter mild T2 hyperintensity with
relative T2 darkness of the dentate nucleus
(A, small white arrow); T2 hypointensity
of the optic radiations and lateral nucleus
of the thalamus (B, small black arrows);
cerebellar atrophy (C, large white arrow);
and T1 isointensity to hyperintensity of
the white matter (D and E), consistent
with a radiologic diagnosis of hypomyeli-
nation.Web Resources
The URLs for data presented herein are as follows:
Ensembl, http://www.ensembl.org/index.html
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
Splice View, http://zeus2.itb.cnr.it/~webgene/wwwspliceview_ex.
html
Human Splicing Finder, http://www.umd.be/HSF/References
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